Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONL1204 in Geographic Atrophy Associated with AMD
NCT04744662Phase 1Completed
- Sponsor
- ONL Therapeutics
- Start
- Jul 2021
- Primary completion
- Feb 2024
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of xelafaslatide in geographic atrophy (GA) (3 arms), sponsored by ONL Therapeutics. Primary endpoints: Best Corrected Visual Acuity up to 48 weeks, Intraocular pressure up to 48 weeks and 1 more. Started Jul 2021; status: completed.
02
Drugs
xelafaslatide
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT04744662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04744662.